Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glucose-6-phosphatase catalytic subunit 2 (G6PC2), also known as IGRP, is an enzyme predominantly expressed in pancreatic β-cells. It modulates glycolytic flux and fine-tunes basal insulin secretion sensitivity by forming a substrate cycle with glucokinase. Genetic variation affects fasting glycemia risk and it serves as an autoimmune target relevant for type 1 diabetes pathogenesis.
Modulation of glucose-6-phosphate hydrolysis to regulate glycolytic flux and insulin secretion
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glucose-6-phosphatase catalytic subunit 2 (G6PC2).